Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
European Heart Journal. Quality of Care & Clinical Outcomes|February 17, 2022
Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS studyKausik K Ray, Nafeesa Dhalwani, Mahendra Sibartie, et al.Advances in Therapy|January 29, 2024
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS StudyMichael Lehrke, Anja Vogt, Volker Schettler, et al.Journal of Cardiovascular Pharmacology and Therapeutics|May 23, 2023
Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS StudyVladimír Blaha, Roman Margoczy, Ivo Petrov, et al.Journal of Clinical Lipidology|October 26, 2017
Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemiaG Kees Hovingh, Frederick J Raal, Ricardo Dent, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 19, 2013
Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidismPablo Ureña-Torres, Ian Bridges, Cynthia Christiano, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 6, 2011
An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND studyJan-Christoph Galle, Kathleen Claes, Istvan Kiss, et al.Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|May 26, 2023
Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS studyAgustín Blanco Echevarría, Juan De Dios García Díaz, Assumpta Caixas, et al.European Journal of Preventive Cardiology|November 12, 2024
Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemiaAlbert Wiegman, Andrea Ruzza, G Kees Hovingh, et al.Journal of the American Heart Association|October 4, 2017
Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in HyperlipidemiaPeter P Toth, Gillian Worthy, Shravanthi R Gandra, et al.Journal of Clinical Lipidology|October 9, 2022
Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemiaDaniel Gaudet, Andrea Ruzza, Ian Bridges, et al.Pageof 3